Valuation: StemCell Institute Inc.

Market Cap 6.56B 41M 37.16M 34.37M 31.01M 58.44M 3.87B 60.5M 413M 164M 2.07B 154M 151M P/E 2026
49.6x
P/E 2027 * 82.4x
Enterprise Value 6.56B 41M 37.16M 34.37M 31.01M 58.44M 3.87B 60.5M 413M 164M 2.07B 154M 151M EV / Sales 2026
2.74x
EV / Sales 2027 * 2.25x
Free-Float
22.67%
Yield 2026 *
-
Yield 2027 * -
1 day-3.98%
1 week+1.88%
Current month-7.13%
1 month-11.31%
3 months-14.00%
6 months-4.55%
Current year-17.91%
1 week 634
Extreme 634
678
1 month 628
Extreme 628
730
Current year 627
Extreme 627
976
1 year 627
Extreme 627
976
3 years 627
Extreme 627
2,411
5 years 627
Extreme 627
3,285
10 years 627
Extreme 627
3,610
Manager TitleAgeSince
Director of Finance/CFO - -
President 53 01/06/2016
Chief Administrative Officer - -
Director TitleAgeSince
Director/Board Member 53 01/09/2013
Director/Board Member 82 01/06/2015
Director/Board Member 67 01/06/2020
Change 5-day change 1-year change 3-year change Capi.($)
-3.98%+1.88%-18.62%-69.52% 41M
-0.49%+6.56%+14.83%+30.44% 114B
-0.32%+0.82%+5.59%+110.06% 104B
-1.19%+2.71%+56.20%+512.22% 46.27B
+0.62%+2.17%+10.06%+99.55% 33.33B
-0.49%+1.07%+38.81%+78.08% 30.08B
-0.02%+1.55%+38.86%+94.05% 28.56B
-0.29%+0.95%+48.27%+389.27% 22.76B
-0.70%-1.71%-18.92%-19.23% 19.92B
+1.15%+2.99%-4.11%+34.18% 17.15B
Average -0.57%+1.97%+17.10%+125.91% 42B
Weighted average by Cap. -0.34%+2.79%+19.54%+134.56%

Financials

2026 2027 *
Net sales 2.87B 17.95M 16.27M 15.05M 13.58M 25.58M 1.69B 26.49M 181M 71.67M 904M 67.37M 65.94M 2.92B 18.26M 16.55M 15.31M 13.81M 26.03M 1.72B 26.95M 184M 72.92M 920M 68.54M 67.08M
Net income 180M 1.13M 1.02M 944K 851K 1.6M 106M 1.66M 11.34M 4.49M 56.71M 4.22M 4.14M 80M 500K 453K 419K 378K 713K 47.18M 738K 5.04M 2M 25.2M 1.88M 1.84M
Net Debt - -
Projected Income Statement - Annual - StemCell Institute Inc.
Logo StemCell Institute Inc.
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Employees
117
Date Price Change Volume
13/11/26 ¥651.00 -3.98% 41,700
12/11/26 ¥678.00 +1.50% 5,600
11/11/26 ¥668.00 +3.89% 4,500
10/11/26 ¥643.00 +1.26% 5,200
09/11/26 ¥635.00 -0.63% 9,100

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - StemCell Institute Inc.
  1. Stock Market
  2. Stocks
  3. 7096 Stock